세계의 불면증 시장 보고서 : 치료 유형별, 약물 유형별, 유통 채널별, 지역별(2024-2032년)

The global insomnia market size reached US$ 5.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.6 Billion by 2032, exhibiting a growth rate (CAGR) of 2.69% during 2024-2032.

Insomnia is a sleep disorder that can lower energy levels and affect the mood, health, work performance, and overall life quality of an individual. Its common causes include stress, long travels, hectic work schedules, poor sleep habits, binge eating, and excessive consumption of nicotine, caffeine, and alcohol. It can also be associated with mental health disorders, such as post-traumatic stress, and the use of drugs like antidepressants for asthma or blood pressure and over-the-counter (OTC) for pain relief, allergy, and cold. Its treatment options, such as cognitive-behavioral therapy (CBT), OTC sleep aids, and prescription medications like Eszopiclone and Ramelteon, are currently available worldwide.

Insomnia Market Trends:

The coronavirus disease (COVID-19) pandemic generated unprecedented changes in lives, including social isolation and innumerable work challenges and family obligations. This acts as a major stressful event that impacted the sleep patterns of millions and strengthened the market growth. Moreover, medical conditions, such as chronic pain, cancer, diabetes, heart disease, asthma, gastroesophageal reflux disease (GERD), overactive thyroid, Parkinson's disease, and Alzheimer's disease, are usually linked with insomnia. Hence, the increasing number of individuals suffering from these ailments is driving the demand for insomnia medications. Apart from this, hormonal shifts during the menstrual cycle and menopause can lead to the risk of developing insomnia, which is contributing to the market growth. In addition, as changes in sleep patterns, activity, and health and the rising use of prescription drugs can increase the chance of insomnia among older people, the growing geriatric population globally is catalyzing the demand for insomnia medical treatment. Furthermore, increasing investments in testing new treatments, interventions, and tests to prevent, detect, treat, and manage insomnia are anticipated to drive the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global insomnia market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on therapy type, drug class and distribution channel.

Breakup by Therapy Type:

Non-Pharmacological Therapy

Hypnotherapy

Cognitive Behavioral Therapy

Medical Devices

Others

Pharmacological Therapy

Prescription Sleep Aids

Over-The-Counter Sleep Aids

Breakup by Drug Class:

Antidepressants

Melatonin Antagonist

Benzodiazepines

Nonbenzodiazepines

Orexin Antagonist

Others

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Drug Stores

Online Pharmacies

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Astellas Pharma Inc., Aurobindo Pharma Limited, Biocodex, Eisai Co. Ltd., Mallinckrodt Pharmaceuticals, Merck & Co. Inc., Neurim Pharmaceuticals Inc., Pfizer Inc., Sanofi S.A., Sumitomo Dainippon Pharma Co. Ltd. (Sumitomo Chemical Co. Ltd.), Takeda Pharmaceutical Company Limited and Vanda Pharmaceuticals Inc.

Key Questions Answered in This Report

• 1. What was the size of the global insomnia market in 2023?
• 2. What is the expected growth rate of the global insomnia market during 2024-2032?
• 3. What are the key factors driving the global insomnia market?
• 4. What has been the impact of COVID-19 on the global insomnia market?
• 5. What is the breakup of the global insomnia market based on the therapy type?
• 6. What is the breakup of the global insomnia market based on the drug class?
• 7. What are the key regions in the global insomnia market?
• 8. Who are the key players/companies in the global insomnia market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Insomnia Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Therapy Type

• 6.1 Non-Pharmacological Therapy
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 Hypnotherapy
    • 6.1.2.2 Cognitive Behavioral Therapy
    • 6.1.2.3 Medical Devices
    • 6.1.2.4 Others
  • 6.1.3 Market Forecast
• 6.2 Pharmacological Therapy
  • 6.2.1 Market Trends
  • 6.2.2 Key Segments
    • 6.2.2.1 Prescription Sleep Aids
    • 6.2.2.2 Over-The-Counter Sleep Aids
  • 6.2.3 Market Forecast

7 Market Breakup by Drug Class

• 7.1 Antidepressants
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Melatonin Antagonist
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Benzodiazepines
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Nonbenzodiazepines
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Orexin Antagonist
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Others
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast

8 Market Breakup by Distribution Channel

• 8.1 Hospital Pharmacies
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Retail Pharmacies
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Drug Stores
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Online Pharmacies
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Astellas Pharma Inc.
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 Aurobindo Pharma Limited
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
  • 14.3.3 Biocodex
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
  • 14.3.4 Eisai Co. Ltd.
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 Mallinckrodt Pharmaceuticals
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
  • 14.3.6 Merck & Co. Inc.
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 Neurim Pharmaceuticals Inc.
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
  • 14.3.8 Pfizer Inc.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Sanofi S.A.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 Sumitomo Dainippon Pharma Co. Ltd. (Sumitomo Chemical Co. Ltd.)
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis
  • 14.3.11 Takeda Pharmaceutical Company Limited
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
    • 14.3.11.3 Financials
    • 14.3.11.4 SWOT Analysis
  • 14.3.12 Vanda Pharmaceuticals Inc.
    • 14.3.12.1 Company Overview
    • 14.3.12.2 Product Portfolio
    • 14.3.12.3 Financials